Puma Biotechnology Inc
Închisă
SectorSănătate
9.08 -0.87
Rezumat
Modificarea prețului
24h
Minim
8.9
Maxim
9.16
Venit | 12M 8.2M |
|---|---|
Vânzări | 12M 57M |
P/E Medie Sector | 18.726 56.597 |
EPS | 0.16 |
Marjă de profit | 14.493 |
Angajați | 179 |
EBITDA | 14M 14M |
Următoarele câștiguri | 5 nov. 2026 |
|---|
Capitalizare de piață | 89M 493M |
|---|---|
Deschiderea anterioară | 9.95 |
Închiderea anterioară | 9.08 |
Sentimentul știrilor
By Acuity
50%
50%
136 / 339 Clasament în Healthcare
Puma Biotechnology Inc Grafic
Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.
Știri relevante
Comparație
Modificare preț
Puma Biotechnology Inc Așteptări
Sentiment
By Acuity
136 / 339 Clasament în Sănătate
Sentimentul știrilor
Neutral
Volatilitate
Sub medie
Volumul știrilor (RCV)
Peste medie
Date financiare
Cheltuieli de vânzare și administrare
Cheltuieli de exploatare
Profit pre-impozitare
Vânzări
Costul vânzărilor
Profit brut din vânzări
Cheltuieli cu dobânzile pe datorie
EBITDA
Profit operațional
$
Despre Puma Biotechnology Inc
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.